Authors

• Torben Kasparek
• Iryna Lobach
• Thrasyvoulos Tzellos (ORCID: https://orcid.org/0000-0003-2356-0847)
• Angelo Valerio Marzano (ORCID: https://orcid.org/0000-0002-8160-4169)
• Christos C. Zouboulis (ORCID: https://orcid.org/0000-0003-1646-2608)
• Αthanassios Kyrgidis (ORCID: https://orcid.org/0000-0003-3896-0309)
• Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
• Teresa Bachhuber
• Angela Llobet Martinez
• Afsáneh Alavi (ORCID: https://orcid.org/0000-0003-1171-4917)
• Hessel H. van der Zee (ORCID: https://orcid.org/0000-0002-2874-7726)
• Magdalena B. Wozniak (ORCID: https://orcid.org/0000-0002-4411-2747)
• N. Thomas (ORCID: https://orcid.org/0000-0002-0146-0071)
• Gregor B. E. Jemec (ORCID: https://orcid.org/0000-0002-0712-2540)
• Christine‐Elke Ortmann
• Shoba Ravichandran

Institutions

• University of Copenhagen (DK)
• Novartis (Switzerland) (CH)
• Mayo Clinic (US)
• University of Milan (IT)
• Aristotle University of Thessaloniki (GR)
• Nordland Hospital Trust (NO)
• Erasmus MC (NL)
• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
• Novartis (United States) (US)
• Hospital de Manises (ES)
• Medizinische Hochschule Brandenburg Theodor Fontane (DE)
• Novartis (Ireland) (IE)
• G. Papanikolaou General Hospital (GR)

Publication Details

Journal

Journal of the European Academy of Dermatology and Venereology

Published

2024-10-19

DOI

https://doi.org/10.1111/jdv.20369

Citations

8

Primary Topic

Hidradenitis Suppurativa and Treatments

Type

article

Field-Weighted Citation Impact

4.28

Funders

• Novartis